0.22-0.28) was strongly correlated with CFU content as well as ALDH br content of the CBU. These results suggest the ALDH br segment assay is a reliable assessment of potency that allows rapid selection and release of CBUs based on unit characteristics measured before release from the cord blood bank to the transplant center for transplantation.
Introduction
Banked unrelated donor cord blood is an important source of allogeneic cells for hematopoietic stem cell transplantation (HSCT). Benefits of cord blood include rapid procurement, minimal risk to the donor, lower risk of graft-versus-host disease in the recipient and more permissive human leukocyte antigen (HLA) matching [1] [2] [3] [4] [5] . Despite these benefits, delays in engraftment or primary graft failure are observed in 10-15% of patients after transplantation [6] [7] [8] . Many graft failures may be due to low potency, the ability of the cord blood unit (CBU) to restore hematopoiesis after HSCT.
CBUs are selected by transplant centers (TC) using HLA matching along with CBU characteristics of potency measured before cryopreservation, including the total nucleated cell count (TNCC), myeloerythroid and mixed hematopoietic progenitor colony forming units (CFU) and CD34 + cell content, often adjusted for cell dose.
Freezing, storage and thawing of CBUs reduce the overall potency. Precryopreservation measures would not reflect potential insults that could affect the potency of the transplanted unit [9] [10] [11] . Potency markers measured on a representative sample of the thawed CBU closer to the time of transplant would more accurately predict the capacity of the unit to engraft in the transplant setting. Previous work in our laboratory showed CFUs measured on thawed CBUs are predictive of neutrophil engraftment and survival post-transplant 12 . However, CFU assays are typically scored two weeks after the unit has been transplanted. Therefore, an assay is needed to assess the potency of the CBU before final selection and release to the TC. ALDH br is highly expressed in hematopoietic stem and progenitor cells [13] [14] [15] [16] [17] . 18 . Transplantation of purified ALDH br human cord blood progenitors into immunodeficient, interleukin-2 receptor-gamma null (NSγ) mice results in lymphoid and myeloid reconstitution 19 . Accordingly, we developed a potency assay based on ALDH br expression in cord blood cells.
For the past 10 years, it has been common practice at cord blood banks to heatseal the tubing through which the cryobag was filled as a series of blood-containing segments remain attached to the unit. These segments can be removed individually without compromising the integrity of the CBU and are used for confirmatory typing (CT)
of the HLA match prior to final selection of a CBU for transplantation. As HLA-typing requires only a small amount of blood, the remainder of blood in the segment is available for potency testing.
We now describe the development and validation of an in vitro flow cytometric assay measuring ALDH br cell content of a CBU-segment for evaluating potency of a CBU during CT. We consider the CFU assay as the best available laboratory surrogate for clinical engraftment and therefore prospectively compared the correlation of CFU content of 3,908 segments from a public cord blood bank with several flow parameters.
Our results suggest that the ALDH br cell content of segments is the parameter that is most highly correlated with CFU. Therefore, ALDH br content is likely to be the best parameter measured to predict the ability of a CBU to engraft.
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Materials and Methods: Control Segment Preparation
Fresh CBUs excluded from banking in the Carolinas Cord Blood Bank (CCBB) were processed to generate segments that serve as assay controls. Hetastarch (6%, Hospira, Lake Forest, IL) was sterilely added to the CB collection bag at a 1:5 ratio, the CB bag docked to a Sepax cell separation kit (CS-530.1, Biosafe Systems, Houston, TX) and processed on a Sepax-1 system using the program for cord blood volume reduction and RBC depletion. Mononuclear cells were collected in a volume of 20 mL.
The output bag was inserted into a Coolmix device (Biosafe) and 5 mL dimethyl sulfoxide (Akron Biotech, Boca Raton, FL) (DMSO, 55% in 5% Dextran 40) was added (1mL/min) using a Fusion One Syringe Infusion Pump (Chemyx, Inc., Stafford, TX) 
Thawing, washing and staining of cord blood removed from CBU Segments
After removal from liquid nitrogen storage, the segments were kept on dry ice until thawed. A segment was thawed by holding it between the fingers, then wiped with alcohol and placed on a sterile gauze pad. The blood was aspirated into a syringe using a 25-gauge needle and dispensed into Dextran-Albumin (DA, 100 µL). DA was prepared by adding human serum albumin (25% HSA, Octapharma, Hoboken, NJ) to dextran 40 (10% in 0.9% sodium chloride, Hospira) for a final concentration of 5% HSA. All segments were processed before proceeding to the next steps. The blood and DA was mixed by shaking the tube and incubated at room temperature for 10 min followed by 
Plating and Enumeration of Post Thaw Colony Forming Assay
An aliquot of cells from the CFU assay tube was diluted 1:10 in Cellpack solution (Sysmex America) and counted on a XE-1000i. The volume containing 1.0 X 10 5 cells was calculated and added to 2 mL of MethoCult (#H4434, STEMCELL Technologies).
The sample was vortexed, allowed to sit for two minutes and plated into four wells (0.4
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From mL each) in the middle of a 24-well plate. Sterile water was added to the outer wells for humidification. The plates were incubated at 37 o C in a humidified incubator with 5% CO 2 for 14 days. CFU colonies, including erythroid burst forming units (BFU-E), granulocyte macrophage (CFU-GM) and granulocyte, erythrocyte, macrophage, and megakaryocyte (CFU-GEMM) colony forming units were counted using a CKX41 inverted, phase-contrast microscope (Olympus America, Center Valley, PA) and a 40x objective and reported as the mean colony count per 1.0 X10 5 WBC. Total CFUs were calculated by adding the totals of the CFU-GM, CFU-GEMM and BFU-E. 
Validation of the Potency Assay

Assessment of Intermediate Precision
Intermediate precision was measured by two operators, each testing segments prepared from five CBU on two Accuri C6 flow cytometers on six different days. All test samples consisted of segments prepared for the validation from randomly chosen cord blood units. Segments were stored in LN 2 to mirror storage of the actual segments on a CBU. Variability was assessed by comparing the ALDH br (as a percent of viable CD45) from each sample. The CV was reported as segments from each CBU as a whole for both operators and instruments, and by assessing operators and instruments separately. 
Assessment of Specificity
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Assaying Thawed or Fresh Units
Prior to cryopreservation, 100 uL of fresh blood taken from a CBU was diluted in For
Correlation of Segment Potency with Engraftment
A search of our clinical database identified 78 single-cord transplants performed at Duke using single cord blood unit grafts that represented either the initial or the only transplant for that patient. Characteristics measured on segments from the transplanted units were examined to determine whether they predict of neutrophil engraftment (3 consecutive days of ANC > 500/µL) using plots of the cumulative incidence function of each segment biomarker with differences determined by Gray's test. Death prior to engraftment (1 patient) and graft failure (4 patients) were treated as competing risks.
Results
We developed and validated a segment-based rapid assay to determine potency of cryopreserved CBUs selected for consideration for HSCT prior to release from a FDA licensed public cord blood bank. 
Intermediate Precision
The segments from five CBUs were assayed by two operators on two cytometers on six different days, analyzed separately and collated. The data was reanalyzed with respect to overall sample precision across both operators and instruments ( were chosen randomly, comparisons between the CBUs were not performed.
Specificity
We tested specificity by determining whether we could detect 5,000 ALDH br cells spiked into varying concentrations of cord blood mononuclear cells. Acceptance was scored by detecting between 4,000 and 6,000 ALDH br cells in a background of 1-10 million contaminating cells. This was met at all levels of cell background with CVs ranging from 0.6-9.0% (Figure 4 ). The largest variation (9.0%) was seen in the samples with the highest background contamination, in which the ALDH br concentration was 100
fold less than that seen in routine clinical samples. In the range of typical CBU samples, (Table 2) .
We examined the correlation of ALDH br cells to CFUs in the segments tested. CBUs and frozen segments ( Figure 6A ) revealed a weak correlation (Spearman r=0.43) with segments tending to have a lower ALDH br content. To determine the correlation of the potency assay between segments and bags and cryopreservation, research units from the CCBB were randomly selected, the entire unit thawed and assayed along with the distal segment that would normally be assayed in for CT ( Figure 6B ). While there was a strong overall correlation between segments and units (Spearman r=0.88), segments still tended to underestimate the ALDH br content of the unit.
ALDH br Impact on Engraftment
We asked whether ALDH . The association between segment-based ALDH br and CFU in this subset of segments was similar to that observed in the entire sample of segments included in our study (r=0.70, P < 0.001). We observed a trend towards faster engraftment with increased expression of ALDH br (P=0.03, Figure 7 ), although caution is warranted in interpretation of this result due to small subgroup sizes. CFU and CD34 did not predict neutrophil engraftment in the entire cohort (P > 0.05 for all; data not shown).
Discussion
Our results demonstrate the successful development of a segment-based potency assay that meets ICH guidelines for Accuracy, Specificity, Precision, Repeatability, and Linearity. Furthermore, we have demonstrated through a prospective evaluation of almost 4,000 segments from cryopreserved CBU that the assay: (1) is highly correlated with CFUs, which have been previously shown to best predict neutrophil engraftment after UCBT; and (2) can be efficiently integrated into routine cord blood banking release procedures during the CT process before final selection and release of the CBU to the TC.
Currently, CBUs are selected 3,21-23 by a transplant center after review of the precryopreservation TNCC, HLA matching and/or CD34 + cell content. These data fail to reflect insults to the CBU caused by freezing and thawing of the unit. Therefore, we focused on post-thaw CBU characteristics or surrogates for these measures. We previously reported that post-thaw CFU content best correlated with engraftment for both neutrophils and platelets 12, 24 . While post-thaw CFU content showed the strongest correlation with engraftment, it is not feasible to use this parameter for CBU selection since it is generally scored 14 days after plating the assay.
The established correlation of CFU and ALDH br cells in fresh CBU and the availability of segments at the time of CBU selection led us to develop and optimize the ALDH br assay on thawed CBU segments. This approach posed some technical challenges that had to be resolved for successful measurement of potency. In order to maintain cell viability and protect the cells from DMSO cytotoxicity during thawing, we followed a DA wash protocol based on a method by Rubinstein 25 which emulates CBU washing for transplantation. We demonstrated that the temperature during this step was critical and cells and DA needed to be at room temperature to avoid loss of detectable ALDH br cells. This contrasts protocols applied to CBUs that requires washing the cells with ice cold DA.
In these studies, we also observed that ALDH br content of the segments correlates well with the CFU content. This finding strongly suggests that measurement of ALDH br can serve as a surrogate for the CFU assay. The stronger correlation between segments and frozen units, as opposed to fresh units, likely means that cryopreservation impacts both segments and units with possible greater impact on the segments. This means that the segment assay may disqualify some adequate potency units from being used. However, the segment assay is highly unlikely to identify low potency units as high potency units. As the potency assay data is available at the time of final donor selection, it can be used as a prospective potency assay for selecting CBUs. Our data suggest that CBUs rich in ALDH br cells are predictive of engraftment but confirmatory studies are needed. This would be expected as this enzyme is characteristically highly expressed in the hematopoietic stem and progenitor cells from human umbilical cord blood 15, 26 , bone marrow 27, 28 and mobilized peripheral blood 29, 30 .
Other methods to assess engraftment potential of CBUs have been reported in the literature. Higher post-thaw CD34 + viability has been correlated with the dominant unit after double CBU transplantation and low CD34 + viability is associated with an increased risk of graft failure 31, 32 . Additionally, dominant unit CD34 + infused cell dose predicts engraftment after double-unit transplantation 33 . In addition, the use of the HALO ATP bioluminescence assay on segments and units indicates that potency assessment on the mononuclear cell (MNC) fraction may be more robust and less variable than on the TNCC fraction 34 . Further refining of the CFU assay to decrease the length of the assay is also under investigation 35, 36 . The creation of Cord Blood Apgar utilizing precryopreservation and post-thaw graft variables (TNCC, MNC, CFU, CD34 + , and volume)
showed a composite scoring system could be used to optimize selection of CBUs for 
